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A B S T R A C T
Background: Information on the current and future numbers of Australian men living with prostate
cancer is limited. We describe a method for estimating complete prevalence of prostate cancer to provide
a measure of the burden of prostate cancer in Australia.
Methods: Prostate cancer data from the New South Wales (NSW) Central Cancer Registry were used with
PIAMOD (Prevalence and Incidence Analysis MODel) software to estimate future prostate cancer
prevalence in NSW. We ﬁrst ﬁtted parametric incidence and survival models then used the modelled
incidence and survival estimates to calculate complete prevalence. The estimated and projected
prevalence incorporate past observed trends and take into account different assumptions about future
survival trends. These models were validated against observed prevalence from the counting method.
Results: Based on data for 1996–2007, the number of men living with prostate cancer in NSW was
estimated to rise by 59% to 73%, from 38,322 in 2007 to 60,910–66,160 in 2017. The increasing incidence
rates and the ageing population were the major contributors to this estimated increase. Validation
suggested that these projections were reasonable, as the estimated prevalence in 1996–2007 was in
good agreement with the corresponding prevalence calculated using the direct counting method, and
the incidence models were supported by the recent data on prostate-speciﬁc antigen testing.
Conclusions: As the number of men living with prostate cancer is expected to increase dramatically in the
next decade in Australia, representing a signiﬁcant challenge to the health system, careful planning and
development of a healthcare system able to respond to this increased demand is required. These
projections are useful for addressing the challenge in meeting the cancer care needs of men with prostate
cancer.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Contents lists available at ScienceDirect
Cancer Epidemiology
The International Journal of Cancer Epidemiology, Detection, and Prevention
jou r nal h o mep age: w ww.c an cer ep idem io log y.n et1. Introduction
Prostate cancer has become the most frequently diagnosed
cancer among men in developed countries around the world [1],
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3.0/).burden on health services in most high income countries, although
it can be difﬁcult to accurately assess the full extent of this burden.
While it is fortunate that most prostate cancer patients live with
the disease for many years after diagnosis, this does mean that the
traditional cancer surveillance measures of incidence and mortali-
ty, which cover only the two extreme ends of the disease spectrum
(diagnosis and death), are insufﬁcient measures of the true
magnitude of the disease burden in a given population. In this
regard, cancer prevalence – deﬁned as the number or proportion of
people alive in a population at a given date who have been
diagnosed with the disease – provides information that is crucial toe under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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in the period following primary treatment and before death from
prostate cancer.
There are, however, some signiﬁcant challenges in determining
the true prevalence of prostate cancer. Population-wide data used
to estimate prevalence usually lag 3 to 5 years behind the current
year due to the time required for data collection, compilation, and
dissemination [3]. Moreover, prevalence estimates using observed
data from cancer registries can only provide limited duration
prevalence (e.g. 1-year prevalence or 5-year prevalence), as the
majority of population-based cancer registries in the world have
not been established long enough to capture all prior cancer
diagnoses [4]. Thus, an estimate of the complete prevalence is often
derived from observed data using statistical models, which can
also be extended to estimate future prevalence.
Estimating future prostate cancer prevalence is particularly
complicated due to the changes in patterns of incidence and
survival that have occurred since the introduction of prostate-
speciﬁc antigen (PSA) testing in the late 1980s [5]. These marked
changes mean that historical data are a relatively unreliable
foundation for modelling prevalence. In a recent report comparing
the four most widely used age–period–cohort (APC) models to
project cancer incidence in Canada, none of the approaches was
found to work well for prostate cancer [6]. As a result of this, some
authors avoided including prostate cancer [7] when they predicted
future cancer incidence for major cancer types due to the
uncertainty in the projections.
In this study, we used a valid PIAMOD (Prevalence and
Incidence Analysis MODel) method [8] and data from an Australian
population-based cancer registry to estimate the future prevalence
of prostate cancer in the state of New South Wales (NSW).
2. Methods
The software we used in this study, PIAMOD [8], estimates and
projects cancer prevalence as a function of modelled incidence and
survival estimates. A more detailed description of the methods for
using PIAMOD software to estimate future cancer prevalence can
be found in previous publications [9,10]. In brief, the process of
using the software to estimate prevalence involves three principal
steps: modelling incidence (by ﬁtting APC models to obtain
incidence projections), modelling survival (by ﬁtting a mixture
cure model), and then the estimation and projection of complete
prevalence. These steps are illustrated in Fig. 1, and the data andFig. 1. Flow chart showing the use of PIAMOD for estimating future cancer
prevalence.methods involved in each of these steps will be described in detail
below.
2.1. Data
Incidence data for ﬁrst primary prostate cancer (ICD-O3 C61)
[11] diagnosed in 1972–2007 were extracted from the NSW
Central Cancer Registry database. The Registry covers a population
of 7.2 million people, approximately one-third of the national
population of Australia, and maintains a record of all cases of
cancer diagnosed in NSW residents since 1972 [12]. The Registry
generally has high standards of data completeness and quality, and
the data are accepted by the International Agency for Research on
Cancer for publication in Cancer Incidence in Five Continents
[13,14]. We included cases aged 18–84 years at diagnosis and
excluded cases who were reported to the registry through death
certiﬁcate only (DCO), or who were ﬁrst identiﬁed post-mortem.
The proportion of DCO cases in the Registry, an indicator of the
quality of the cancer registry, is generally low (1.0% for 1993–1997
[15] and 0.9% for 2004–2008 [16]). Other input data required by
the PIAMOD software were obtained from the Australian Bureau of
Statistics (ABS): all-cause mortality data for NSW by single year of
age and year (1972–2007), and the corresponding mid-year NSW
residential male population data by single year of age and calendar
year. Data on PSA tests performed (1996–2012) from Medicare
Australia were used as a complementary validation for the ﬁtted
incidence models [17].
Cases were followed up for survival status to 31 December
2007 through record linkage of the cancer cases in the Cancer
Registry with the death records from the NSW Register of Births,
Deaths and Marriages and the National Death Index. 2007 was the
most recent year for which follow up data were available. This
signiﬁcant lag was caused by the ABS reviewing its processes for
release of its data including cause of death (http://www.cancer-
institute.org.au/data-and-statistics/accessing-our-data/availabili-
ty-of-nsw-central-cancer-registry-data#death-why-2008).
2.2. Ethics statement
This study involves analysis of routinely collected data and the
records were de-identiﬁed (name, address, date of birth had been
removed) before being provided to the research team. As a large
proportion of the individuals would likely have moved or died
since their diagnosis of cancer, which could have been up to
40 years ago, it would have been impracticable to seek consent, and
thus the NSW Population and Health Service Research Ethics
Committee waived the conditions for consent and approved the
study (reference number: 2009/03/139).
2.3. Modelling incidence
Incidence rates are one of the main factors in predicting future
cancer prevalence. Prostate cancer incidence changed dramatically
in Australia with the introduction of PSA testing in the late 1980s. A
sharp initial increase in the early 1990s (which peaked in 1994 at
187 cases per 100,000 men) was followed by a fall of 10% per year
to a minimum of 126 per 100,000 men in 1998, and then another
increase during 2001–2005 [18]. This incidence pattern poses a
statistical challenge in terms of accurately projecting future
incidence trends. While incidence data are available for 1972 on-
wards we chose to follow the approach used by previous
researchers [19] and modelled incidence using data from
1996 to 2007. Selecting this period potentially helps reduce some
of the impact of the introduction of PSA testing on our incidence
models.
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the generalised linear model (GLM), the generalised additive model
(GAM) and the Bayesian model. We used the GLM polynomial
method in this study, implemented using the PIAMOD software
[8]. This approach considers age, year of diagnosis and birth cohort as
continuous variables, and uses a smoothing method, a polynomial
function, to ﬁt the data. In the polynomial method, age, period and
cohort trends are modelled by log-linear regression for the mean
parameter of the Poisson distribution. For our analysis the linear
term for period was excluded when estimating the parameters in
order to avoid the collinearity due to the linear relationship between
age, period and cohort [8]. The regression coefﬁcients were obtained
using the maximum likelihood method.
The parameters of the APC models were estimated using
observed incidence for 1996–2007 and then this model was used
for forward (after 2007) and backward (before 1996) projections.
The resulting ﬁtted incidence estimates were used as inputs for
estimating future prevalence (for 2008–2017). The most appro-
priate model was selected based on the likelihood ratio statistic
(LRS) combined with knowledge of the epidemiology of prostate
cancer in Australia because ‘. . .forecasting is not possible without
sufﬁcient knowledge of the epidemiology of a given cancer. . .’ [20].
2.4. Modelling survival
A two-step procedure was used to model survival. First, relative
survival was estimated and tabulated, and then a mixture cure
model was ﬁtted to the tabulated relative survival estimates.
Survival relative to the general population was calculated in this
study because we used all-cause mortality data from a population-
based cancer registry. We derived tabulated relative survival for
prostate cancer from incidence and follow-up data using the Pohar–
Perme method [21]. In line with the modelling of incidence we also
used data for the period 1996–2007 for modelling survival. This
period was chosen because survival patterns from the earlier period
of 1972–1995 were markedly different from the survival patterns
that occurred after the introduction of PSA testing, and the pre-PSA
testing patterns would be unlikely to occur again in the future.
We modelled these tabulated relative survival estimates with a
mixture cure model [22], which assumes that patients can be
divided into two distinct groups based on their prognosis: those who
are cured and those who are not. The deﬁnition of ‘cure’, as used in
this context, is that ‘cured’ patients have a mortality rate equal to
that of people of the same age and sex in the general population
[22]. The model parameters are then the proportion cured and the
scale and shape parameters of the Weibull distribution, which was
assumed to describe the survival distribution for the uncured
patients. The model parameters were estimated by means of a non-
linear regression procedure using PROC NLIN (SAS code provided by
Roberta De Angelis) and taking the inverse of the variances of the
observed survival as weights [22]. In this study, the Weibull mixture
model was stratiﬁed by age group (18–64, 65–74 and 75–84 years)
so parameters were estimated for each age stratum at the reference
year of diagnosis (central point of the period 1996–2007), and the
period effect varied by age.
The modelled survival estimates were extrapolated backward
to 1972 and forward to 2017, using the assumption that the
survival trends would be dynamic and would have the same ‘slope’
as that for the 1996–2007 observed data. The model-based
estimates of survival from this mixture cure model were used
as inputs into PIAMOD for the next step of the analysis.
2.5. Prevalence projections
Prostate cancer prevalence was then estimated using PIAMOD
software with the modelled prostate cancer incidence, model-basedrelative survival, and all-cause mortality as inputs. Because
PIAMOD can only provide results for closed age groups and
populations, our prevalence estimates include cases up to age
84 years only. Further details on the PIAMOD method have been
previously described by Mariotto et al. [23]. The PIAMOD
prevalence estimates for 1996–2007 were validated by compar-
ing the estimated prevalence with the limited duration preva-
lence estimates derived by counting the number of cases
diagnosed between 1972 and 2007 [24], which is considered to
be the most reliable estimate for populations covered by a registry
for a sufﬁcient length of time [25].
2.6. Sensitivity analyses
Further analyses were also undertaken to investigate the effects
of different assumptions regarding future incidence rates and
survival on the estimated future prevalence. First, we estimated the
future prevalence by choosing two different APC incidence models.
Second, we estimated prostate cancer prevalence based on the
assumption that the future survival rate will remain constant at the
level observed in 2007 rather than continuing to follow the trends in
the observed data. Third, we repeated the primary analyses using
data with longer survival follow-up (1990–2007) to assess the
sensitivity of the cure model to the length of follow-up and its impact
on the projected prevalence. Finally, we assumed that there would
be no changes in incidence rates in future years, so the 2007 age-
speciﬁc prevalence rates were applied to the projected 2017 age-
speciﬁc male population in NSW. This gave an estimate of the
prevalence in 2017 due to population growth and ageing only.
3. Results
A total of 49,866 cases of ﬁrst primary prostate cancer were
diagnosed in 1996–2007 in NSW. After excluding 2685 cases aged
85 years or over, 47,181 cases (median age: 69 years) were
included in the incidence and prevalence analyses.
3.1. Incidence models
Six relatively simple APC models (APC101, 102, 201, 202, 103,
and 301) were plotted against the observed incidence and are
shown in Fig. 2. To select which models were most appropriate for
predicting future incidence trends beyond the available data for
NSW (to 2007), the projected incidence trends from these models
were compared to more recent observed incidence data for
prostate cancer from similar jurisdictions: data from another
Australian state up to 2012 [26], and from the United States [27]
and New Zealand [28]. All these data suggest that from around
2008–2010 prostate cancer incidence tended to stabilise or even
fall. In addition, NSW data on PSA testing have also shown a trend
towards a reduction in the number of PSA tests being performed
(Fig. 3), which in turn is likely to result in a slower increase in
prostate cancer incidence [29]. Thus the APC models 102 and 103,
which showed slower increasing incidence trends, were consid-
ered to be the most appropriate models with which to project
incidence for 2008–2017 (Fig. 2). The model-ﬁt-statistics (Appen-
dix) also suggest that these two models are a reasonably good ﬁt to
the observed incidence data.
3.2. Survival models
Five-year prostate cancer relative survival trends (assuming
dynamic survival beyond the observed data window) by year of
diagnosis are shown in Fig. 4. It can be seen that the ﬁtted values for
ﬁve-year relative survival were in close agreement with the
observed data for the period 1996–2007.
Fig. 2. Comparison of age–period–cohort incidence models and observed incidence rates for prostate cancer in NSW, Australia.
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Based on these data, the number of men with prostate cancer in
NSW is projected to rise by approximately 59% to 73% in 10 years:
from 38,322 in 2007 to 60,910–66,160 patients in 2017 (Table 1).
Fig. 5 shows the PIAMOD prevalence estimates based on data from
1996 to 2007 (with APC 102 and 103 incidence models) as well as
the observed prevalence (to 2007). We observed (Fig. 5) that the
PIAMOD estimates (1996–2007) were in good agreement with the
prevalence (1996–2007) calculated from the direct counting
method using observed data from 1972 to 2007.
For the sake of brevity, we only present sensitivity analysis
results from incidence model APC 102 here (Table 2). It suggested
that the impact of variations in survival (either assuming a
constant trend or using a longer time series) on the projected
prevalence was limited (2%). This is due to the high survival for
prostate cancer, which means there is very little room for further
improvement. If the effect of the growth in the ageing population isFig. 3. Estimated age-standardised prostate cancer incidence rates (1972–2007), and proj
2012) in NSW, Australia.solely considered, prostate cancer prevalence is estimated to
increase by 26% from 2007 to 2017.
4. Discussion
This study used population-based cancer registry data and the
PIAMOD software to model current and future prostate cancer
prevalence in NSW. Our results indicated that in the 10 years from
2007 to 2017 the number of men living with a diagnosis of prostate
cancer in NSW is likely to rise by between 59% (low bound) and 73%
(high bound). We found that for the period 1996–2007 there was
close agreement between the ﬁtted and observed prevalence, so
we believe that our predictions are reasonable and that the true
future prevalence is likely to lie between these two predictions. We
would however, like to emphasise that there is considerable
uncertainty in these projections, and that our models are likely to
become less accurate as time passes, especially considering howected incidence rates (1996–2017) and age-standardised rates of PSA testing (1996–
Fig. 4. Comparison of ﬁtted ﬁve-year relative survival with observed survival data for prostate cancer in NSW, Australia.
Table 1
Estimated (2007) and projected (2017) prevalence of prostate cancer in NSW,
Australia.
2007 (Baseline) estimate Projected prevalence estimates in 2017 and
percent increase from baseline
Lower
bounda
%
Increase
Upper
boundb
%
Increase
38,322 60,910 59% 66,160 73%
a Based on incidence model APC 102.
b Based on incidence model APC 103.
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behaviours.
Despite the difﬁculties involved, several previously published
international studies have estimated future prostate cancer
prevalence. Gatta et al. [30] used the completeness index method
with data from 76 European cancer registries, and reported a 17.6%
increase in prostate cancer prevalence from 2003 to 2010 due to
demographic changes (which is a very similar result to our
estimates of increase in prevalence due to population changes
only: 2.5% vs 2.6% annual increase). An American study by Mariotto
et al. [31] used the PIAMOD method [8] and data from 9 SEERFig. 5. Comparison of PIAMOD estimated complete prevalenceregistries, and estimated a 41.3% increase in prostate cancer
prevalence from 2010 to 2020. Given the different methods, time
periods and data used in these studies it is very difﬁcult to make
any direct comparisons between these studies and ours, but it does
seem at least that the prediction of an increasing trend in prostate
cancer prevalence is common amongst studies in developed
countries.
Several Australian studies of cancer prevalence [32–34]
provided estimates of limited duration prevalence. This means
that they reported the number of people alive at the date of interest
with a diagnosis of cancer within a past speciﬁc number of years
(e.g. 2, 10, or 25 years). Our 36 year prevalence estimate at
2007 was comparable to those reported by the Cancer Institute
NSW [33] and the Australian Institute of Health and Welfare
(AIHW) [34], although different time periods were used in these
studies. This close agreement is not surprising, as the results were
based on the same (Cancer Institute NSW report) or similar (AIHW
report) data sources. However, our study extended these results by
providing estimates of the future prevalence that are more useful
for health service planning for prostate cancer patients. Extrapo-
lating these projections to the national population would equate to
about 185,700 to 201,700 men living with prostate cancer in
Australia in 2017, representing a signiﬁcant challenge to the and observed data for prostate cancer in NSW, Australia.
Table 2
Impact of various factors on the projected prevalence of prostate cancer in 2017, NSW Australia.
2007 (Baseline) estimate Projected number of prevalent cases (2017) using different assumptionsa
Assuming constant
survival trend
% Change Based on data
for 1990–2007
% Change Based on population
changeb only
% Change
38,322 60,313 57% 60,163 57% 48,269 26%
a Incidence model APC 102 was used in these analyses.
b Population projections from the Australian Bureau of Statistics (2007).
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be underestimated because we did not include cases aged 85 years
or over in the estimation and those with second primary prostate
cancer. There would be approximately 6922–7518 men aged
85 years or older living with prostate cancer in NSW in 2017 if we
apply the proportion of cases in this oldest group in 2007 (for
which we have data) to the projected 2017 total prevalence in
NSW. The corresponding national ﬁgure would be between 21,103
and 22,922 prevalent cases aged over 85 years; this highlights the
importance of including the elderly population in studies of cancer
survivors.
The advantage of the method we used is that the models for
incidence and survival were ﬁtted separately, similar to the
method adopted by Crouch et al. [35], with the estimates of future
prevalence being obtained as a product of both. This method allows
us to construct and evaluate different scenarios regarding future
incidence and survival, as well as population ageing, and to model
their effects on future prevalence estimates.
Our models are based on both statistical and clinical founda-
tions. First, most projection models for prostate cancer are likely to
be poor due to the ﬂuctuation in incidence caused by the
introduction of PSA testing in the late 1980s [6] and this would
inevitably lead to biased estimates of both incidence and
prevalence. Hence, from a statistical point of view it is well
justiﬁed to exclude the period where the data ﬂuctuate consider-
ably, as has also been done by other researchers [19]. As a general
rule, it is more appropriate to separate the patient population into
a set of homogeneous groups and exclude those groups that add
little value to the modelling of future incidence and prevalence.
Therefore, the more recent data have greater predictive power than
much older data, and in the case of prostate cancer this is
particularly important, as the introduction of PSA testing has
signiﬁcantly altered the way in which disease ﬁrst presents and its
subsequent management. Modelling the recent data allows for a
more clinically relevant prediction of future prevalence.
Projections of cancer prevalence depend on the estimates and
assumptions of future trends in incidence and survival. We found
that the projected incidence trend was the most important factor
in estimating future prostate cancer prevalence, as was shown in
the results, with the estimated prevalence being very sensitive to
the incidence models selected. For example, if we chose incidence
model APC 202, which had the lowest LRS (Appendix), this would
result in a 164% increase in prostate cancer prevalence by 2017
(rather than 59–73%), which we believe to be highly unlikely. This
demonstrates that it may be risky to select the incidence model
based on statistical assessment criteria only, and shows why an
understanding of the epidemiology of the cancer under study is
extremely important for the selection of the most appropriate
models for predicting future trends.
Based on the models we selected, there would be much slower
growth in the incidence rates of prostate cancer in the period
2008–2017 than was seen from 2001 onward, and it tended to
ﬂatten out near the end of the period. Based on our understanding
of the driving forces behind changes in prostate cancer incidence
and independent data from similar jurisdictions [26–28], webelieve these assumptions are reasonable. Many studies show an
association between the level of PSA testing and prostate cancer
incidence [18,29,36], so the trend in PSA testing should provide
some insight into the future trends in incidence. Recent data from
the Medicare Beneﬁts Scheme (Australia’s universal health care
scheme) suggested that the peak of PSA testing in NSW may have
been reached, although it still remains at a very high level (Fig. 3).
However, it is as yet unclear how patterns of future prostate cancer
testing in Australia will be affected by recent recommendations
such as those of the U.S. Preventive Services Task Force against
routine PSA screening for men of any age [37], and the American
Urological Association’s more conservative recommendations to
only test men aged 55 to 69 [38]. Evidence from the USA indicates
that the impact is likely to be minimal [39,40].
Age is another important factor in predicting prostate cancer
incidence patterns, as the risk of diagnosis increases exponentially
after age 50. The number of men aged over 65 years in Australia is
projected to increase from 1.23 million in 2006 (representing 12.1%
of the total male population) to 1.78 million (15.7% of the total
male population) in the year 2016 [41]. This ageing of the
population will inevitably lead to a signiﬁcant increase in the
number of men diagnosed with prostate cancer. In regards to the
extent of this increase, incidence projections from Canada and the
USA may provide some insight into future Australian trends, as the
population age structures of these countries are broadly similar to
that of Australia [41]. The incidence in Canada was projected to
increase by 39% from 2009 to 2021 due to population ageing only
[2], while the corresponding increase in the USA is estimated to be
30% over the period 2010 to 2020 [42]. Our projected increase due
to population changes only (26% from 2007 to 2017) is similar to
the estimates from Canada and the USA.
In contrast to the selection of the incidence models, different
assumptions of trends in future survival had less of an impact on
the estimated future prevalence than was seen with changes in
incidence rates and population ageing (Table 2). This may be
because survival rates for prostate cancer are already very high
(ﬁve year relative survival being over 90%). Therefore, a less robust
assumption (of cure) would not have too great an impact on the
predicted prevalence. Sensitivity analysis indicates that the
predicted prevalence estimates were not sensitive to the length
of the survival follow-up.
Cancer prevalence is a function of incidence, survival and
population ageing. It is challenging to completely separate the
contribution of each of these factors, as it is not simply an additive
relationship. For example, an increased incidence of PSA detected
cases will likely lead to prolonged survival even if no improve-
ments in treatment occur. Nevertheless, we conducted sensitivity
analyses designed to investigate the sensitivity of the estimated
future prevalence to different factors. Compared to 2007, our
results indicate that population ageing and growth only would
result in an increase of around 26% in the number of men living
with prostate cancer in 2017 (assuming incidence and survival
remain static for the period 2007–2017). This also implies that the
remaining predicted increase in prevalence for 2017 would be
caused by the increased incidence rates and improved survival. As
X.Q. Yu et al. / Cancer Epidemiology 39 (2015) 29–36 35discussed previously, changes in survival patterns would only
contribute about 2% to the change in the estimated prevalence in
2017, and thus population ageing and increased incidence rates
should be the major contributors to the future increase in
prevalence. Although these results are consistent with previous
international studies [2,42], we would emphasise that it is
extremely difﬁcult to accurately isolate the effects of individual
factors, and the results of this sensitivity analysis only provide a
rough indication of the contribution of each of these variables.
The method used here has several limitations that must be
considered if it is to be applied to other data. As these prevalence
projections are based on assumptions about incidence and
survival, any future changes in the methods used to undertake
prostate biopsy or changes to PSA testing thresholds could have
marked short-term effects, leading to unreliable projections. It is
therefore important to emphasise that these projections are very
sensitive to any future changes in prostate cancer diagnostic
practices and the accuracy of the projections tends to decrease
with time. Thus, we suggest that these projections should be
updated as new data become available and assumption underpin-
ning the projections be periodically reviewed. Also, integrating
data on PSA testing trends and the method and number of biopsy
cores taken with observed incidence data would have increased
the accuracy of our model, but as registry data are not routinely
linked with data on screening history, and the software we used
does not allow for the integration of such factors, this was not
possible. This may warrant further investigation in future
modelling exercises, as the model accuracy could be signiﬁcantly
increased by incorporating data regarding important predictors of
incidence [43]. The ﬁnal limitation of our methods is that the
assumption of cure is not always reasonable for prostate cancer
because of its high survival rate [44]. When cure does not occur, the
mixture cure model used here provides an approximation only
[22]. However, as previously described, we found that a less robust
assumption of cure would only have a small impact on the
predicted prevalence.
Despite these limitations, this study does provide a more
complete measure of the future burden of prostate cancer in
Australia than has previously been available. With an increasing
number of men being diagnosed with prostate cancer and living for
many years after diagnosis, this is an area of research of critical
importance for the planning of healthcare services. Despite its high
prevalence (about 20% of the total cancer survivor population),
research on prostate cancer survivors is relatively rare, with only
5% of all studies of cancer survivors having a speciﬁc focus on these
men [45]. By comparison, breast cancer survivors have been the
focus of 40% on studies of cancer survivors, despite representing a
similar proportion of the survivor population as prostate cancer
survivors (22%) [45]. As prostate cancer prevalence is expected to
increase dramatically in the next decade, it is important that more
is known about this population and that reliable projections of the
future burden are available. It is hoped that this study will begin to
address some of these issues and will help enable an evidence-
based approach to health-care planning and service delivery.
Conﬂict of interest statement
The authors declare that they have no conﬂict of interests.
Authorship contribution
XQY and DOC conceived the project; DPS and MSC assisted with
further reﬁnement of the project. XQY obtained the cancer registry
data, QL performed the data analysis, and XQY provided oversight
of the data analysis with inputs from DOC, DPS and MSC. XQY
drafted the manuscript with help from QL for Section 2 and 3. DOC,DPS, MSC and QL revised the manuscript. All authors read and
approved the ﬁnal version of the manuscript.
Acknowledgements
This work is supported by the Prostate Cancer Foundation of
Australia (PCFA–YI 0410). Both Xue Qin Yu and David Smith are
supported by NHMRC Early Career Fellowships (550002 and
1016598). We would like to thank the NSW Central Cancer Registry
for providing the data for this study and Clare Kahn for editorial
assistance.
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.canep.
2014.11.009.
References
[1] Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics.
CA Cancer J Clin 2011;61:69–90.
[2] Quon H, Loblaw A, Nam R. Dramatic increase in prostate cancer cases by 2021.
BJU Int 2011;108:1734–8.
[3] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin
2013;63:11–30.
[4] Capocaccia R, Colonna M, Corazziari I, De Angelis R, Francisci S, Micheli A, et al.
Measuring cancer prevalence in Europe: the EUROPREVAL project. Ann Oncol
2002;13:831–9.
[5] Neppl-Huber C, Zappa M, Coebergh JW, Rapiti E, Rachtan J, Holleczek B, et al.
Changes in incidence, survival and mortality of prostate cancer in Europe and
the United States in the PSA era: additional diagnoses and avoided deaths. Ann
Oncol 2012;23:1325–34.
[6] Cancer Projection Network (C-projection). Long-term projection methods:
comparison of age–period–cohort model-based approaches. Edmonton,
Canada: Alberta Health Services, 2010.
[7] Dyba T, Hakulinen T. Do cancer predictions work. Eur J Cancer
2008;44:448–53.
[8] Verdecchia A, De Angelis G, Capocaccia R. Estimation and projections of cancer
prevalence from cancer registry data. Stat Med 2002;21:3511–26.
[9] Yu XQ, Clements M, O’Connell D. Projections of cancer prevalence by phase of
care: a potential tool for planning future health service needs. J Cancer Surviv
2013;7:641–51.
[10] Yu XQ, Smith DP, Clements MS, Patel MI, McHugh B, O’Connell DL. Projecting
prevalence by stage of care for prostate cancer and estimating future health
service needs: protocol for a modelling study. BMJ Open 2011;1:e000104.
[11] Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin D, et al. Interna-
tional classiﬁcation of diseases for oncology. 3rd ed. Geneva, Switzerland:
World Health Organisation, 2000.
[12] Yu XQ, O’Connell DL, Gibberd RW, Coates AS, Armstrong BK. Trends in survival
and excess risk of death after diagnosis of cancer in 1980–1996 in New South
Wales, Australia. Int J Cancer 2006;119:894–900.
[13] Parkin DM, Muir CS. Cancer incidence in ﬁve continents. Comparability and
quality of data. IARC Sci Publ 1992;45–173.
[14] Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for
27 sites in the adult population in 2008. Int J Cancer 2013;132:1133–45.
[15] Tracey E, Roder D, Bishop J, Chen S, Chen W. Cancer in New South Wales
incidence and mortality 2003. Sydney: The Cancer Institute NSW, 2005.
[16] Currow D, Thomson W. Cancer in NSW: incidence report 2009. Sydney: Cancer
Institute NSW, 2014.
[17] Australian Government. Medicare Australia Medicare Beneﬁts Schedule (MBS)
item statistics reports. Australian Government; 2014.
[18] Smith DP, Supramaniam R, Marshall VR, Armstrong BK. Prostate cancer and
prostate-speciﬁc antigen testing in New South Wales. Med J Aust
2008;189:315–8.
[19] Moller H, Fairley L, Coupland V, Okello C, Green M, Forman D, et al. The future
burden of cancer in England: incidence and numbers of new patients in 2020.
Br J Cancer 2007;96:1484–8.
[20] Clayton D, Schifﬂers E. Models for temporal variation in cancer rates. II: Age–
period–cohort models. Stat Med 1987;6:469–81.
[21] Perme MP, Stare J, Esteve J. On estimation in relative survival. Biometrics
2012;68:113–20.
[22] Verdecchia A, De Angelis R, Capocaccia R, Sant M, Micheli A, Gatta G, et al. The
cure for colon cancer: results from the EUROCARE study. Int J Cancer
1998;77:322–9.
[23] Mariotto AB, Yabroff KR, Feuer EJ, De Angelis R, Brown M. Projecting the
number of patients with colorectal carcinoma by phases of care in the US:
2000–2020. Cancer Causes Control 2006;17:1215–26.
X.Q. Yu et al. / Cancer Epidemiology 39 (2015) 29–3636[24] Krogh V, Micheli A. Measure of cancer prevalence with a computerized
program: an example on larynx cancer. Tumori 1996;82:287–90.
[25] Gail MH, Kessler L, Midthune D, Scoppa S. Two approaches for estimating
disease prevalence from population-based registries of incidence and total
mortality. Biometrics 1999;55:1137–44.
[26] Thursﬁeld V. In: Thursﬁeld V, Staines C, Giles G, Farrugia H, eds. Cancer in
Victoria: statistics & trends 2012. Melbourne: Cancer Council Victoria, 2013.
[27] Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al.
SEER cancer statistics review, 1975–2011. Based on November 2013 SEER data
submission, posted to the SEER web site. April 2014 ed. Bethesda, MD:
National Cancer Institute, 2014.
[28] Ministry of Health. Cancer: new registrations and deaths 2010. Wellington:
Ministry of Health, 2013, 2013.
[29] Gregorio DI, Kulldorff M, Sheehan TJ, Samociuk H. Geographic distribution of
prostate cancer incidence in the era of PSA testing, Connecticut, 1984 to 1998.
Urology 2004;63:78–82.
[30] Gatta G, Mallone S, van der Zwan JM, Trama A, Siesling S, Capocaccia R, et al.
Cancer prevalence estimates in Europe at the beginning of 2000. Ann Oncol
2013;24:1660–6.
[31] Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of
cancer care in the United States: 2010–2020. J Natl Cancer Inst 2011;103:117–28.
[32] Brameld KJ, Holman CD, Threlfall TJ, Lawrence DM, De Kierk NH. Increasing
‘active prevalence’ of cancer in Western Australia and its implications for
health services. Aust NZ J Public Health 2002;26:164–9.
[33] Tracey E, Baker D, Chen W, Stavrou E, Bishop J. Cancer in New South Wales:
incidence, mortality and prevalence, 2005. Sydney: Cancer Institute NSW,
2007.
[34] Australian Institute of Health and Welfare. Cancer survival and prevalence in
Australia: period estimates from 1982 to 2010. Asia Pac J Clin Oncol
2013;9:29–39.[35] Crouch S, Smith A, Painter D, Li J, Roman E. Determining disease prevalence
from incidence and survival using simulation techniques. Cancer Epidemiol
2014;38:193–9.
[36] Smith DP, Armstrong BK. Prostate-speciﬁc antigen testing in Australia and
association with prostate cancer incidence in New South Wales. Med J Aust
1998;169:17–20.
[37] Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force
recommendation statement. Ann Intern Med 2012;157:120–34.
[38] Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, et al. Early
detection of prostate cancer: AUA guideline. J Urol 2013;190:419–26.
[39] Drazer MW, Huo D, Schonberg MA, Razmaria A, Eggener SE. Population-based
patterns and predictors of prostate-speciﬁc antigen screening among older
men in the United States. J Clin Oncol 2011;29:1736–43.
[40] Pollack CE, Platz EA, Bhavsar NA, Noronha G, Green GE, Chen S, et al. Primary
care providers’ perspectives on discontinuing prostate cancer screening. Can-
cer 2012;118:5518–24.
[41] Australian Institute of Health and Welfare. Older Australia at a glance 4th
edition. 4th ed. Canberra: AIHW, DOHA, 2007.
[42] Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer
incidence in the United States: burdens upon an aging, changing nation. J Clin
Oncol 2009;27:2758–65.
[43] Pickle LW, Hao Y, Jemal A, Zou Z, Tiwari RC, Ward E, et al. A new method of
estimating United States and state-level cancer incidence counts for the
current calendar year. CA Cancer J Clin 2007;57:30–42.
[44] Yu XQ, De Angelis R, Andersson TM, Lambert PC, O’Connell DL, Dickman PW.
Estimating the proportion cured of cancer: some practical advice for users.
Cancer Epidemiol 2013;37:836–42.
[45] Harrop JP, Dean JA, Paskett ED. Cancer survivorship research: a review of the
literature and summary of current NCI-designated cancer center projects.
Cancer Epidemiol Biomarkers Prev 2011;20:2042–7.
